Stanford transplants human cortex organoids into cortex-scarce mice

Stanford Medicine scientists have transplanted laboratory-grown human cortical organoids into mice engineered to lack most of their own cerebral cortex, creating what they call "xenocortical" mice, according to a study published online Sept. 16, 2026 in Nature and detailed by Stanford Medicine.

Senior author Sergiu Pasca and colleagues say the approach lets researchers study human neural tissue from genes and cell types through circuits and behavior in a living animal, something living human brain tissue almost never allows for ethical reasons.

Space without a cortex

The team genetically engineered "apallial" mice so starter cells that normally build much of the neocortex and hippocampus never form. Reuters reported those mice retain only about 2% of ordinary cortical content, leaving room for grafts. Stanford Medicine said the animals survived in generally healthy condition, looked broadly like normal mice, yet showed subtler quirks such as a more cautious gait and weaker memory of novel environments.

Into 2-day-old apallial pups, the researchers surgically placed human cortical organoids, typically more than one per animal and each with roughly 100,000 cells, Stanford Medicine reported. About three months later, more than 90% by volume of the animals' cortical tissue was human, and human neurons were integrating into circuits that reached the mouse nervous system.

Pasca stressed terminology in Reuters coverage: labels such as "humanized mice," "mice with human brains," or "mini-brains" misstate the work. The animals keep a mouse nervous system that hosts a large volume of developing human cortical tissue.

Rare cells and a disease proof of concept

The grafts produced a broad mix of cortical cell types, including von Economo neurons, a rare, large class previously seen mainly in postmortem human tissue and linked to social awareness circuits. Stanford Medicine said they had not appeared in dish culture or in earlier, more crowded transplant setups.

In a proof-of-concept injury model, xenocortical mice exposed to five hours of low oxygen showed substantial damage to human-origin cortex and gait or balance problems resembling cerebral palsy-related motor issues, while ordinary and apallial mice were virtually unaffected, Stanford Medicine reported. Pasca framed that as a window on uniquely human vulnerability to perinatal oxygen deprivation.

MIT Technology Review reported that mice with human grafts performed better on a maze memory test than cortex-depleted peers, suggesting the tissue contributes to some cognition. Pasca told Technology Review he is not concerned the rodents have human-like capacities given brain size and evolutionary distance, and he called transplanting similar organoids into cortex-depleted primates a clear ethical red line.

Why it matters, and the limits

Pasca told Stanford Medicine the platform should speed work on disorders rooted in early circuit development, including schizophrenia, epilepsy, profound autism, and cerebral palsy, and enable drug screening in patient-derived cells. The team said ethicists, neurobiologists, patient advocates, philosophers, and legal scholars advised the program, including at an Asilomar meeting Pasca organized in November 2025.

What remains open is how far graft-driven behavior will map onto human disease and which therapeutics will clear early safety gates. Stanford University's Office of Technology Licensing holds related organoid patents and a provisional transplant application listing Pasca and co-authors among inventors.